Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.

about

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.

Item

http://www.wikidata.org/entity/Q42173770

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical implications of cytog ...... a patients with TP53 deletion.

@en

Clinical implications of cytog ...... a patients with TP53 deletion.

@nl

type

Item

label

Clinical implications of cytog ...... a patients with TP53 deletion.

@en

Clinical implications of cytog ...... a patients with TP53 deletion.

@nl

prefLabel

Clinical implications of cytog ...... a patients with TP53 deletion.

@en

Clinical implications of cytog ...... a patients with TP53 deletion.

@nl

P1476

Clinical implications of cytog ...... a patients with TP53 deletion.

@en

P2093

Adrian A Carballo-Zarate

http://www.w3.org/2001/XMLSchema#string

Donna M Weber

http://www.w3.org/2001/XMLSchema#string

Elisabet E Manasanch

http://www.w3.org/2001/XMLSchema#string

L Jeffrey Medeiros

http://www.w3.org/2001/XMLSchema#string

Lianghua Fang

http://www.w3.org/2001/XMLSchema#string

Pei Lin

http://www.w3.org/2001/XMLSchema#string

Rachel L Sargent

http://www.w3.org/2001/XMLSchema#string

Sergej N Konoplev

http://www.w3.org/2001/XMLSchema#string

Sheeba K Thomas

http://www.w3.org/2001/XMLSchema#string

Suyang Hao

http://www.w3.org/2001/XMLSchema#string

P2860

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

International staging system for multiple myeloma.

Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies.

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

P2888

modpathol.2017.63

P304

1378-1386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2017.63

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert Z Orlowski

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090294676

http://www.w3.org/2001/XMLSchema#string

P698

28664940

http://www.w3.org/2001/XMLSchema#string

P932

5628266

http://www.w3.org/2001/XMLSchema#string